Page 253 of 294: studies 2,521 to 2,530 of 2,939, newest first. Back to the psychedelic-assisted therapy overview
Journal of Psychopharmacology 2022 A. H. Young 3 citations
The 21st century has seen a dramatic flow and ebb in the fortunes of clinical psychopharmacology particularly with regard to antidepressants. For about 20 years, perhaps from about 1985 onwards, the tide flowed in with many ‘new’ drugs being made available to clinicians. In mood and psychotic disorders, these were essentially incremental advances from old drugs such as amitriptyline and...
Psi Chi Journal of Psychological Research 2022 Catherine N. Conway, Lisa E Baker 6 citations
Recent clinical trials indicate favorable therapeutic outcomes of psychedelic-assisted psychotherapy for anxiety and treatment-resistant depression. Whereas the neurobiological systems underlying these effects are not well understood, animal behavioral models can serve to investigate these mechanisms. For the current study, we implemented 2 rodent models predictive of anxiolytic drug effects, a...
2022 Davi Mello Castanheira, Andréa da Silva Torrão
INTRODUÇÃO: O Transtorno de Estresse Pós-Traumático (TEPT) é definido como uma condição na qual um indivíduo que sofreu um evento traumático revisita a experiência na forma de lembranças, sonhos ou episódios dissociativos de flashback. A psicoterapia é considerada como primeira opção para o tratamento de TEPT, mas também se utiliza a farmacoterapia com os ISRS paroxetina e sertralina. Os...
Current Topics in Behavioral Neurosciences 2022 Gabrielle Agin-Liebes, Alan K. Davis 16 citations
Depression is highly prevalent and represents the leading cause of global disability and primary contributor to overall global burden of disease. Several lines of evidence from early-phase experimental trials suggest that serotonergic psychedelics, particularly psilocybin, with therapeutic support show great promise in the treatment of depression with large effect sizes. Neuroimaging data have...
Revista Virtual de Química 2022 João Pedro Evangelista Ferreira, Stella Bortoli, Airton Vicente Pereira 1 citation
Depression and anxiety disorders are a major challenge for modern psychiatry, especially when shown to be resistant to conventional means of treatment. Over the past decade, psychedelic and entactogen substances, once stigmatized, have regained an ever-growing momentum as potential therapeutic agents for these disorders. The present study offers a review and comparison of the pharmacological...
Current Topics in Behavioral Neurosciences 2022 Tasha L. Golden, Susan Magsamen, Clara C. Sandu et al. 89 citations
The health and well-being impacts of art and aesthetic experiences have been rigorously studied by a range of disciplines, including cognitive neuroscience, psychiatry, public health, and translational clinical research. These experiences, encompassed in the concepts of set and setting, have long been claimed to be pivotal in determining the acute and enduring effects of psychedelic...
Current Topics in Behavioral Neurosciences 2022 Matthew W. Johnson 31 citations
This manuscript reviews research suggesting that classic psychedelics (5-HT2A receptor agonists) are effective in treating addictions including tobacco use disorder. I review historical research from the 1950s to 1970s suggesting that classic psychedelics are associated with addiction recovery across pharmacologically distinct drugs of addiction. I then review anthropological reports about...
Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022 Daisuke Ibi
Recently, FDA approved psilocybin, the psychoactive substance found in the magic mushroom, as a "breakthrough therapy" for depression; however, its detailed mechanism remains unknown. Serotonergic psychedelics such as psilocybin and LSD have hallucinatory effect through stimulation of serotonin 5-HT2A receptor (5-HT2A), motivating us to investigate the role of 5-HT2A stimulation in...
Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022 Daisuke Ibi
Serotonergic psychedelics such as psilocybin, the psychoactive substance found in the magic mushroom, have hallucinatory effect through stimulation of the cortical serotonin 5-HT2A receptor (5-HT2A). Recently, FDA has called psilocybin a 'breakthrough therapy' for severe depression. We have already demonstrated that 5-HT2A in the lateral septum (LS) plays a responsible role in...
Drug Science, Policy and Law 2022 Rayyan Zafar, Dustin Sulak, Jaime Brambila et al. 3 citations
A 49-year-old woman was diagnosed with an ER + , PR-, HER2 + , BRCA- invasive ductal carcinoma which progressed metastatically to include bone, liver, and lymph node involvement. Standardised care included a 26-month treatment period with targeted chemotherapy and a ketogenic diet. The patient also began a course of cannabinoid-based therapy, consisting initially of a titrated high-dose...